Quality of Life in 265 Patients with Gastroenteropancreatic or Bronchial Neuroendocrine Tumors Treated with [177Lu-DOTA0,Tyr3]Octreotate

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Nuclear Medicine

• Publication date

  2011-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2967/jnumed.111.087932PMID 21795361
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

  2011cited by this paper
• Relationship Between Quality of Life and Health-Related Measures Including Symptoms, Biochemical Markers And Tumor Burden

  2010cited by this paper
• Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

  2010cited by this paper
• European Organization for Research and Treatment of Cancer

  2010cited by this paper
• Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial

  2010cited by this paper
• Peptide-receptor radionuclide therapy for endocrine tumors

  2009cited by this paper
• Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

  2009cited by this paper
• Activity of sunitinib in patients with advanced neuroendocrine tumors.

  2009cited by this paper
• Health and Quality of Life Outcomes

  2009cited by this paper
• Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group.

  2009cited by this paper
• Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

  2008cited by this paper
• Activity of sunitinib in patients with advanced neuroendocrine tumors.

  2008cited by this paper
• Medical Management of Pancreatic Neuroendocrine Tumors

  2008cited by this paper
• Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

  2008cited by this paper
• One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

  2008cited by this paper
• Health related quality of life and psychosocial function among patients with carcinoid tumours. A longitudinal, prospective, and comparative study

  2007cited by this paper
• Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.

  2007cited by this paper
• Role of liver transplantation in the management of unresectable neuroendocrine liver metastases.

  2007cited by this paper
• Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study.

  2006cited by this paper
• Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours.

  2006cited by this paper
• Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.

  2006cited by this paper
• Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

  2005cited by this paper
• Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.

  2004cited by this paper
• Incidence and management of malignant digestive endocrine tumours in a well defined French population

  2004cited by this paper
• Ablative Therapies for Liver Metastases of Gastroenteropancreatic Endocrine Tumors

  2004cited by this paper
• Management of neuroendocrine tumours.

  2004cited by this paper
• A 5‐decade analysis of 13,715 carcinoid tumors

  2003cited by this paper
• Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

  2003cited by this paper
• Understanding self-rated health.

  2002cited by this paper
• Multicollinearity in prognostic factor analyses using the EORTC QLQ‐C30: identification and impact on model selection

  2002cited by this paper
• Incidence trends and risk factors of carcinoid tumors

  2001cited by this paper
• Health-related Quality of Life, Anxiety and Depression in Patients with Midgut Carcinoid Tumours

  2001cited by this paper
• Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients.

  2001cited by this paper
• The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors

  2000cited by this paper
• Epidemiology of carcinoid neoplasms in Vaud, Switzerland, 1974–97

  2000cited by this paper
• Management of neuroendocrine tumours.

  1999cited by this paper
• Interpreting the significance of changes in health-related quality-of-life scores.

  1998cited by this paper
• Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.

  1997cited by this paper
• EORTC QLQ-C30 Scoring Manual

  1995cited by this paper
• Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.

  1993cited by this paper
• The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

  1993cited by this paper
• Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group.

  1993cited by this paper
• Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

  1992cited by this paper
• Karnofsky memorial lecture. An odyssey in the land of small tumors.

  1987cited by this paper
• Food and Drug Administration requirements for approval of new anticancer drugs.

  1985cited by this paper
• One hundred years after.

  1959cited by this paper

• Radiopharmaceutiques à visée thérapeutique : indications, précautions d’emploi et principaux résultats

  2025cites this paper
• Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors

  2025cites this paper
• Theranostics in Lung Neuroendocrine Tumors.

  2025cites this paper
• 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in metastatic phaeochromocytomas and paragangliomas (mPPGL): a single centre retrospective analysis of experience at an ENETS Centre of Excellence

  2025cites this paper
• Impact of treatment on quality of life in neuroendocrine neoplasms survivors.

  2025cites this paper
• Radioactivity levels in the saliva of patients undergoing targeted radioligand therapy with [177Lu]Lu-PSMA-I&T and [177Lu]Lu-DOTA-TOC

  2025cites this paper
• Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs)

  2024influential citation
• Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma – A Meta-analysis

  2024cites this paper
• How to design a theranostic trial?

  2024cites this paper
• Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers

  2024cites this paper
• Sequencing of Somatostatin-Receptor–Based Therapies in Neuroendocrine Tumor Patients

  2024cites this paper
• Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force

  2024cites this paper
• Peptide Receptor Radionuclide Therapy Using 90Y- and 177Lu-DOTATATE Modulating Atherosclerotic Plaque Inflammation: Longitudinal Monitoring by 68Ga-DOTATATE Positron Emissions Tomography/Computer Tomography

  2024cites this paper
• Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours

  2024cites this paper
• On the suitability of an electron beam evaporator as a lutetium atom source

  2024cites this paper
• Improved health‐related quality of life during peptide receptor radionuclide therapy in patients with neuroendocrine tumours

  2023cites this paper
• Techniques de médecine nucléaire pour l’imagerie et traitement des néoplasies neuroendocrines gastro-entéro-pancréatiques

  2023cites this paper
• Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE

  2023cites this paper
• 225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic

  2023cites this paper
• Neuroendocrine Tumor Therapy Response Assessment.

  2023cites this paper
• The Effects of Radioligand Therapy on Quality of Life and Sexual Function in Patients with Neuroendocrine Neoplasms

  2022cites this paper
• Prospective Cohort Real-World Study on Neuroendocrine Tumor Patient's Quality of Life During Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE

  2022cites this paper
• Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now

  2022cites this paper
• Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors

  2022cites this paper
• A Multinational Pilot Study on Patients’ Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires

  2022cites this paper
• Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review

  2022cites this paper
• Relationship between somatostatin receptor expressing tumour volume and health‐related quality of life in patients with metastatic GEP‐NET

  2022cites this paper
• Radioligand therapy — personalized treatment for patients with neuroendocrine tumors

  2022influential citation
• Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial

  2022cites this paper
• Peptide Receptor Radionuclide Therapy

  2022cites this paper
• Imaging and treatment with 68Gallium and 177Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung

  2022cites this paper
• Peptide Receptor Radionuclide Therapy Using 177 Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment

  2022cites this paper
• A Clinical Guide to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Neuroendocrine Tumor Patients

  2022cites this paper
• SPECT/CT in Neuroendrocrine Tumours

  2021cites this paper
• The psychological impact of COVID‐19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability

  2021cites this paper
• 90Y/177Lu-DOTATOC: From Preclinical Studies to Application in Humans

  2021cites this paper
• PEPTIDE RECEPTOR RADIONUCLIDE THERAPY

  2021cites this paper
• Estimation of Health-Related Utilities for 177Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities

  2021cites this paper
• Theragnostics in Neuroendocrine Tumors.

  2021cites this paper
• Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features

  2021cites this paper
• Palliative Interventions for Metastatic Neuroendocrine Tumors

  2021cites this paper
• Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome

  2021cites this paper
• Medical treatment of neuroendocrine neoplasms

  2021cites this paper
• 68Ga-DOTATATE PET/CT Imaging of Refractory Pituitary Macroadenoma Invading the Orbit.

  2021cites this paper
• Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World

  2021cites this paper
• Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE

  2021cites this paper
• Health-related quality of life in neuroendocrine neoplasms: a critical review.

  2020cites this paper
• Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience

  2020cites this paper
• PRRT: identikit of the perfect patient

  2020cites this paper
• Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

  2020cites this paper
• Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.

  2020cites this paper
• Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors

  2020cites this paper
• Satisfaction and quality of life in patients with symptomatic gastroenteropancreatic neuroendocrine tumours treated with lanreotide Autogel in South Africa

  2020cites this paper
• Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE in Advanced Neuroendocrine Tumours (NETs) in a Limited Resource Environment

  2020cites this paper
• The therapeutic efficacy of 177Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors

  2020cites this paper
• Peptide Receptor Radionuclide Therapy

  2020cites this paper
• Small intestinal neuroendocrine tumours - Disease models, tumour development, and remedy

  2019cites this paper
• Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.

  2019cites this paper
• Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls

  2019cites this paper
• Peptide Receptor Radiotherapy: Current Approaches and Future Directions

  2019cites this paper
• Comparison and clinical implementation of quality of life tools in patients with small bowel neuroendocrine tumors treated with Lu-DOTA-TATE PRRT

  2019cites this paper
• Metastatic MEN1 Syndrome Treated with Lutetium-177 – A Case Report

  2019cites this paper
• Integrating Early Rapid Post-Peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting.

  2019cites this paper
• The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE

  2019cites this paper
• Patient Eligibility Criteria for PRRT According to the European Neuroendocrine Tumor Society 2017 Guidelines

  2019cites this paper
• Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review

  2019cites this paper
• Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors

  2019cites this paper
• Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

  2018cites this paper
• Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.

  2018cites this paper
• S2k-Leitlinie Neuroendokrine Tumore

  2018cites this paper
• Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives

  2018cites this paper
• Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review

  2018cites this paper
• Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine

  2018cites this paper
• Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy.

  2018cites this paper
• Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy

  2018cites this paper
• Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients

  2018cites this paper
• Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.

  2018cites this paper
• Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome

  2018cites this paper
• The College of Nuclear Physicians of South Africa Practice Guidelines on Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours.

  2018cites this paper
• Health-Related Quality of Life in Patients with Small Intestine Neuroendocrine Tumors

  2018cites this paper
• Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting

  2018cites this paper
• Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms

  2018cites this paper
• Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

  2018cites this paper
• PRRT with Radiolabeled Peptides: Indications, Procedures, and Results

  2018cites this paper
• Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors

  2018cites this paper
• TheranosTics and precision medicine special feaTure: review arTicle Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy

  2018cites this paper
• Radiolabeled Somatostatin Analogues in the Treatment of Non-GEP-NET Tumors

  2018cites this paper
• Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects

  2018cites this paper
• Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors

  2018cites this paper
• Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines

  2018cites this paper
• Multidisciplinary management of refractory insulinomas

  2018cites this paper
• Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives

  2018cites this paper
• Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.

  2018cites this paper
• Tratamiento con 177LU-DOTATATE en tumores neuroendocrinos. Estudio preliminar

  2017cites this paper
• Targeted Therapy for Medullary Thyroid Cancer: A Review

  2017cites this paper
• 177Lu-DOTATATE treatment in neuroendocrine tumours. A preliminary study.

  2017cites this paper
• Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies.

  2017cites this paper
• Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET

  2017cites this paper
• Treatment with 177Lu-DOTATATE: Past, present and future.

  2017cites this paper
• ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

  2017cites this paper